<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186221</url>
  </required_header>
  <id_info>
    <org_study_id>OCS-LVR10202019</org_study_id>
    <nct_id>NCT04186221</nct_id>
  </id_info>
  <brief_title>OCS Liver PROTECT Continued Access Protocol</brief_title>
  <official_title>Continued Access Protocol To Evaluate the Effectiveness of the Portable Organ Care System (OCS) Liver for Preserving and Assessing Donor Livers for Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continued Access Protocol to evaluate the effectiveness of the OCS Liver System to preserve
      and assess donor livers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single arm, continued access protocol to evaluate the effectiveness of the OCS
      Liver System to preserve and assess donor livers having one or more of the following
      characteristics:

        1. Donor age equal to or greater than 40 years old, or

        2. Expected cross clamp time of 6 hours or greater, or

        3. Donor after circulatory death (DCD) with age less than or equal to 55 years; or

        4. Steatotic lever &gt;0% and less than or equal to 40% at time of retrieval, based on
           pre-retrieval histology)

      A maximum of 21 sites will enroll up to 184 transplanted liver recipients. The primary
      effectiveness endpoint will be the incidence of Early Allograft Dysfunction (EAD) or primary
      non-function.

      All recipients will be followed for 24 months from the date of transplantation (some of which
      will be post-market).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single-arm, continued access protocol</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of EAD or primary non-function</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of early allograft dysfunction or primary non-function of donor liver</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OCS donor liver assessment during perfusion</measure>
    <time_frame>During OCS perfusion, on average 4 hours</time_frame>
    <description>Collection of liver perfusion parameters while on OCS device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival at Day 30 post-transplantation</measure>
    <time_frame>30 days</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival at initial hospital discharge post liver transplantation</measure>
    <time_frame>30 days</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of initial post-transplant ICU stay</measure>
    <time_frame>ICU days, on average 5 days</time_frame>
    <description>ICU stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of initial post-transplant hospital stay</measure>
    <time_frame>Hospital days, on average 10 days</time_frame>
    <description>Hospital stay</description>
  </other_outcome>
  <other_outcome>
    <measure>Evidence of ischemic biliary complications diagnosed at 6 and 12 months post transplant</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Ischemic biliary complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Extend to reperfusion syndrome as assessed based on the rate of decrease of lactate</measure>
    <time_frame>anhepatic phase, 30-40 minutes after hepatic artery and portal vein reperfusion, 90-120 minutes after reperfusion of the transplanted liver</time_frame>
    <description>Reperfusion syndrome</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathology sample score for liver samples</measure>
    <time_frame>Procedure (Pre-retrieval, Post-OCS preservation (on average, 4 hours), post reperfusion 90-120 min after reperfusion and prior to abdominal closure)</time_frame>
    <description>Pathology sample scoring</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Liver System</intervention_name>
    <description>OCS Liver System for preserving and assessing donor livers for transplantation</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:

          -  Registered primary liver transplant candidate, male or female

          -  Age ≥ 18 years

          -  Signed (1) written informed consent document and (2) authorization to use and disclose
             protected health information

        Exclusion Criteria:

          -  Acute, fulminant liver failure

          -  Prior solid organ or bone marrow transplant

          -  Chronic use of hemodialysis or diagnosis of chronic renal failure, defined as chronic
             serum creatinine of &gt; 3 mg/dl for &gt; 2 weeks and/or requiring hemodialysis

          -  Multi-organ transplant

          -  Ventilator dependent

          -  Dependent on &gt; 1 IV inotrope to maintain hemodynamics

        Donor Inclusion Criteria

          -  Donor age ≥ 40 years, or

          -  Expected cross-clamp time ≥ 6 hours, or

          -  Donor after circulatory death (DCD) with age ≤ 55 years, or

          -  Steatotic liver &gt; 0% and ≤ 40% macrosteatosis at time of retrieval

        Donor Exclusion Criteria

          -  Living donors

          -  Liver intended for split transplants

          -  Positive serology (HIV, Hepatitis B surface antigen &amp; Hepatitis C)

          -  Presence of moderate or severe traumatic liver injury, or anatomical liver
             abnormalities that would compromise ex-vivo perfusion of the donor liver (i.e.,
             accessory blood vessels or other anatomy that require surgical repair) and livers with
             active bleeding (e.g., hematomas)

          -  Donor livers with macrosteatosis of &gt; 40% based on retrieval biopsy readout.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scripps</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Meyer</last_name>
      <phone>858-554-4340</phone>
      <email>meyer.michelle@scrippshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher L Marsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyler Lunow-Luke</last_name>
      <phone>415-353-8465</phone>
      <email>tyler.lunow-luke@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Garrett Roll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Fish</last_name>
      <phone>813-844-8437</phone>
      <email>tfish@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Amy Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Crisalli</last_name>
      <phone>617-643-4087</phone>
      <email>kcrisalli@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>James Markmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shellie Neuman</last_name>
      <phone>402-552-6240</phone>
      <email>shellie.neuman@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Shaheed Merani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Transplantation</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Alani</last_name>
      <phone>347-671-8217</phone>
      <email>omohamme@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Milan Kinkhabwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Haydel</last_name>
      <phone>212-241-0255</phone>
      <email>brandy.haydel@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Sander Florman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Morgan</last_name>
      <phone>901-478-9184</phone>
      <email>mailto:Melissa.morgan@mlh.org</email>
    </contact>
    <investigator>
      <last_name>Cory Eymard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Carlson</last_name>
      <phone>214-648-7609</phone>
      <email>emily.carlson@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Malcolm MacConmara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

